ProfileGDS5678 / 1429519_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 81% 82% 82% 79% 80% 74% 80% 82% 78% 78% 80% 79% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5456480
GSM967853U87-EV human glioblastoma xenograft - Control 25.8855681
GSM967854U87-EV human glioblastoma xenograft - Control 35.8749482
GSM967855U87-EV human glioblastoma xenograft - Control 46.1182482
GSM967856U87-EV human glioblastoma xenograft - Control 55.6240479
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5274380
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8161674
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5724980
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8662582
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4468278
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3441178
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7322380
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.522779
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6715980